, Volume 12, Issue 1, pp 1-3
Date: 29 Jan 2010

Heparin and Aspirin Versus Aspirin Alone for Prevention of Recurrent Pregnancy Loss

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Laskin CA, Spitzer KA, Clark CA, et al.: Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol 2009, 36:279–287.

Rating

• Of importance

Introduction

The current standard of care for the prevention of recurrent pregnancy loss in women with antiphospholipid antibodies (aPL) is treatment with heparin (unfractionated or low molecular weight) and low-dose acetylsalicylic acid (ASA; aspirin) during pregnancy. Evidence supporting the benefit of this regimen over aspirin alone largely derives from two trials published in the late 1990s [1, 2]. In 2002, however, Farquharson et al. [3] found a high live birth rate with ASA alone and no benefit from the addition of heparin. The recent study by Laskin et al. [4] is an open-label, randomized controlled trial designed to address this important clinical issue.

Aims

This study intended to compare live birth rates in women with recurrent pregnancy loss associated with aPL, coa ...